Douglas A. Treco - 05 Jun 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: Director
Issuer ticker: CRSP
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 17:40:32 UTC
Prior SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Ryland Waldinger

Key filing fact

Douglas A. Treco filed Form 4 for CRISPR Therapeutics AG (CRSP) on 09 Jun 2026.

Key facts

This page summarizes Douglas A. Treco's Form 4 filing for CRISPR Therapeutics AG (CRSP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2026, 17:40.

Change

Previous filing in this sequence was filed on 08 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001688192 Primary reporting owner

Treco Douglas A

Relationship: Director
Address: C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: /s/ Elizabeth Ryland Waldinger
Signature date: 09 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +13,000
Change %
Price: $0.000000^*
Shares after: 13,000
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 13,000
Exercise price: $51.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.